Browse by author
Lookup NU author(s): Professor David KavanaghORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
© 2024 International Society of NephrologyThe term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed to the epidemic, typical form of the disease. Over time, the atypical hemolytic uremic syndrome term has evolved into being used to refer to anything that is not Shiga toxin–associated hemolytic uremic syndrome. The term describes a heterogeneous group of diseases of disparate causes, a circumstance that makes defining disease-specific natural history and/or targeted treatment approaches challenging. A working group of specialty-specific experts in the thrombotic microangiopathies was convened to review the validity of this broad term in an era of swiftly advancing science and targeted therapeutics. A Delphi approach was used to define and interrogate some of the key issues related to the atypical hemolytic uremic syndrome nomenclature.
Author(s): Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, Cuker A, Dixon BP, Fakhouri F, Hingorani SR, Java A, van de Kar NCAJ, Kavanagh D, Leung N, Licht C, Noris M, O'Shaughnessy MM, Parikh SV, Peyandi F, Remuzzi G, Smith RJH, Sperati CJ, Waldman M, Walker P, Vivarelli M
Publication type: Article
Publication status: Published
Journal: Kidney International
Year: 2024
Volume: 106
Issue: 3
Pages: 326-336
Print publication date: 01/09/2024
Online publication date: 20/08/2024
Acceptance date: 22/05/2024
Date deposited: 27/08/2024
ISSN (print): 0085-2538
ISSN (electronic): 1523-1755
Publisher: Elsevier B.V.
URL: https://doi.org/10.1016/j.kint.2024.05.021
DOI: 10.1016/j.kint.2024.05.021
Altmetrics provided by Altmetric
